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Abstract
Background: Managing a severe dengue infection is a challenge specially when complicated by other
comorbidities. We report a patient with dengue haemorrhagic fever and spontaneous bleeding who required
mandatory anticoagulation for a prosthetic mitral valve replacement. This is the first case report in published
literature describing this therapeutic dilemma.
Case presentation: A fifty one year old Sri Lankan woman was diagnosed with dengue haemorrhagic fever with
bleeding manifestations. During the critical phase of her illness, the platelet count dropped to 5,000/ɥl. She was
also on warfarin 7 mg daily following a prosthetic mitral valve insertion. In managing the patient, the risk of
bleeding had to be balanced against the risk of valve thrombosis without anticoagulation. Warfarin was withheld
when the platelet count dropped to 100,000/ɥl and restarted when it recovered above 50,000/ɥl. The patient was
off anticoagulation for 10 days.
Conclusions: We managed this patient with close observation and continuous risk benefit assessments of
management decisions. However, experience with one patient cannot be generalized to others. Therefore, it is
essential that clinicians share their experiences in managing such difficult patients.
Background
Dengue haemorrhagic fever is a potentially lethal illness
that is universally prevalent in the tropics [1]. Severe in-
fection is characterized by a ‘leakage phase’ (or critical
phase) usually lasting 48 hours following an initial febrile
phase [2]. During the leakage phase, an increase in capil-
lary permeability leads to extravasation of fluid and hae-
moconcentration. During the latter stages of febrile
phase and early leakage phase (or even later), there is a
steady drop in platelet count. At occasions, it can drop
as low as 3000/μl in previously healthy individuals (nor-
mal platelet count in a healthy adult: 150,000 – 400,000/
μl). The exact mechanism of this drop is unclear but
presumed to be immunological. The low platelet count
leaves the patient at a significant risk of spontaneous
bleeding. The management is further complicated by
pre-existing co-morbidities that interfere with the usual
therapeutic guidelines. We report a patient with severe
dengue infection with very low platelet counts and
haemorrhagic manifestations who was also on
mandatory anticoagulation with warfarin for a prior
prosthetic mitral valve replacement.
Case presentation
A fifty one year old Sri Lankan woman, presented with
fever for three days and constitutional symptoms such
as arthralgia, myalgia and headache. There was no spe-
cific focus for an infective process such as a urinary or a
respiratory tract infection. She was a diagnosed patient
with tight mitral stenosis (following rheumatic carditis),
for which a metallic mitral valve replacement had been
done eight years ago. She was on lifelong anticoagulant
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therapy with target INR (International Normalized
Ratio) maintained with 7 mg of warfarin per day. Her
other medication included; digoxin for atrial fibrillation,
penicillin prophylaxis for rheumatic valvular disease and
a combination of captopril, spiranolactone and furosem-
ide for heart failure. Physical examination showed pallor,
dental caries and ankle oedema without any peripheral
stigmata of infective endocarditis. On admission, she
was hemodynamically stable with a pulse rate of 82 beats
per minute and a blood pressure of 110/60 mmHg.
There was no postural drop in blood pressure or a nar-
rowed pulse pressure to indicate intravascular volume
depletion. On auscultation, the metallic first heart sound
and a loud pulmonary component of the second heart
sound were heard. Lungs had a few bilateral basal
crackles. Rest of the examination was normal.
The provisional diagnosis was dengue fever as the clin-
ical picture was typical of the infection. However, mea-
sures were taken to exclude an alternative infective
process such as infective endocarditis. Her admission
coincided with a dengue epidemic in the area. Strict
monitoring of vital parameters and appropriate fluid
management was initiated according to the national
guidelines on dengue [2].
The initial full blood counts showed a leucopenia and
a trend of dropping platelet counts confirming our sus-
picion. The dengue antibodies assessed by IgM antibody
capture ELISA (MAC- ELISA) were positive indicating
an acute infection. On day 3 after admission (date of ad-
mission taken as day 0), her fever subsided but there
was evidence of a small right sided pleural effusion indi-
cating the onset of plasma leakage and the start of crit-
ical/leakage phase. The platelet count that was already
low was expected to hit a nadir between days 4–5
(within 48 hours after the start of critical phase). The pa-
tient was at high risk of internal haemorrhage. The usual
management protocol at this time calls for fluid restric-
tion and observation for bleeding manifestations.
Prophylactic platelet transfusions are discouraged. How-
ever, this particular patient had the complication of a
mitral valve replacement needing mandatory anticoagu-
lation. Stopping anticoagulation had the potential life
threatening complication of valve thrombosis while con-
tinuing warfarin had the risk of a torrential internal
haemorrhage aided by an already low platelet count. In
the absence of guidelines or even previous case reports
with similar experience, we managed the patient with in-
stitutional expert opinion.
Fever and vomiting was treated symptomatically with
paracetamol and domperidone. Spiranolactone, capto-
pril and furosemide were temporarily withheld since
admission. Once the platelet count dropped below
100 × 103/μl, warfarin was withheld. Digoxin was con-
tinued at its usual dose of 0.125 μg three times daily.
The rationale for stopping warfarin was to keep the
patient off it during the critical phase until the platelet
count picked up. However, as warfarin has a long half
life, it was necessary to stop it at least two to three
days before the anticipated onset of critical phase. The
plan was to restart warfarin as soon as the platelet
count was back within ‘safe’ margins. It was antici-
pated that the critical phase would only last for
48 hours (which is the typical clinical picture). It was
a race against time and she was closely monitored
both clinically and echocardiographically for evidence
of valve thrombosis.
Three days after stopping warfarin she entered the
critical leakage phase (heralded by the detection of the
pleural effusion). During this time she developed gum
bleeding, petechiae and haemorrhagic blebs reaching a
maximum size of 2 × 2 cm at venepuncture sites in both
arms. During the critical phase, the platelet count
dropped to 5,000/μl. It was decided to transfuse her with
one unit of red cell concentrate and four units of platelet
concentrates at this time. After the transfusion the pa-
tient was haemodynamically stable without any further
evidence of bleeding. Rest of the critical phase was un-
eventful. However, the platelet count did not rise as
expected immediately after the critical phase. It barely
passed 50 × 103/μl on day 11 (6 days after the end of
critical phase) at which point warfarin was restarted at a
dose of 5 mg daily (Table 1). This was not accompanied
with heparin due to the risk of bleeding and heparin
induced thrombocytopaenia. The patient did not develop
a valve thrombosis despite being off anticoagulation for
10 days (assuming the period of retained warfarin activ-
ity due to long half life since stopping warfarin is equal
to the time to regain full anticoagulatory effect after re-
sumption). The target INR was reached within 3 days of
restarting warfarin and the patient was discharged on
day 15. She was free of symptoms with a platelet count
of 260,000/μl when reviewed in clinic one week later.
Further follow up for her cardiac condition was arranged
at the Institute of Cardiology, National Hospital of Sri
Lanka.
Discussion
The incidence of dengue is rising in many countries and
it remains a life threatening illness in the tropics. During
dengue epidemics, large numbers of patients (approxi-
mately thousands) in all age groups are affected. The
natural course of illness and the management approach
can be complicated by underlying co-morbidities of
patients.
As mentioned previously, this patient’s management
during the critical or ‘leakage’ phase of the illness was
complicated by two conflicting life threatening conditions;
a) risk of massive internal haemorrhage or an intracranial
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bleed due to dengue induced thrombocytopaenia and b)
the need to continue warfarin therapy to avoid a valve
thrombosis of the prosthetic mitral valve. Given the lack
of emergency cardiothoracic surgical facilities, a valve
thrombosis could have been fatal in this patient. There-
fore, withholding warfarin was a precarious balancing
act to allow just enough time for the thrombocyto-
paenia to recover and not too long for the valve to
thrombose. Decision making was further complicated by
the long half life of warfarin. In the absence of guide-
lines or even published case reports in this regard, it
was arbitrarily decided that the risk of bleeding would
be significant when the platelet count dropped below
50,000/μl (a cut off value when procedures such as
lumbar puncture and organ biopsies are contraindicated
in thrombocytopaenic patients). Warfarin had to be
stopped well before this mark. It is difficult to predict
the rate of drop in platelet count in dengue as in some
patients it drops drastically during the critical phase.
Adding to the confusion, the critical phase is not syn-
onymous with the period of rapid platelet drop. In
other words, the platelet count may continue to fall or
fail to rise even after the critical phase is over. Critical
phase is only a surrogate marker for the period of rapid
platelet drop. The critical / leakage phase is more cor-
rectly recognized by presence of a pleural effusion or
ascites (clinically or radiologically) [2]. It is assumed
that when the platelet count drops below 100,000/μl,
the patient will go in to the leakage (critical) phase in
the next 24 hours. Taking all in to account, we stopped
warfarin when the platelet count approached 100,000/μl
and anticipated an interval of at least 48 hours before it
dropped below 50,000/μl. The predictions were reason-
ably accurate and gave us the expected time window
for the action of warfarin to wear off.
Prophylactic platelet transfusions are not recommended
in dengue as per national guidelines but as the patient
developed evidence of active bleeding, we proceeded with
transfusions to maintain the platelet count above 20,000/
μl. Unexpectedly, the recovery of platelet count did not
follow once the patient came out of the critical/leakage
phase. It persistently hovered around 20,000-30,000/μl
exceeding the 50,000/μl mark only at day 11. Warfarin
was withheld till then. We preferred the platelet count to
be above 100,000/μl to restart warfarin but already 10 days
had lapsed without anticoagulation.
There are no case reports in published literature to
our knowledge describing the experience in managing
a patient with severe dengue who was also on anticoa-
gulation after a prosthetic cardiac valve insertion
(search in Pubmed with keywords ‘dengue’ and ‘antic-
oagulation’ or ‘warfarin’ in any field). The only case re-
port describing a similar dilemma is by Dan et al. who
describe a patient developing portal vein thrombosis
following a laparoscopic cholecystectomy whose antic-
oagulation had to be delayed due to a concurrent den-
gue infection [3]. In that patient, the platelet count
reached a nadir of 16,000/μl and anticoagulation was
withheld for 6 days since the diagnosis of the portal
vein thrombosis until the platelet count reached
125,000/μl. At that point, the patient was anticoagu-
lated with low molecular weight heparin and later con-
verted to warfarin.
The critical question raised by this experience is
exactly how long can a person on mandatory anticoagu-
lation for a prosthetic heart valve can be off warfarin
without having a valve thrombosis. Clearly we cannot
answer it in relation to dengue patients due to lack of
data but indirect evidence can be drawn by experiences
with patients having intracranial haemorrhages who
were on warfarin [4,5]. Even then, there are only expert
recommendations (no trial evidence) that suggest
restarting anticoagulation within 3–10 days in patients
whose anticoagulation is mandatory [6].
Table 1 A summary of investigation results of the patient during the illness
Date 9/7/2011 10/7/11 11/7/11 12/7/11 13/7/11 14/7/11 15/7/11 20/7/11 22/7/11
Platelet count (X103/ɥl) 95 79 44 16 07 05* 20 52 70
Packed cell volume (%) 35.5 32.7 34.3 34.8 35.1 34.1 34 33.2 34.3
Haemoglobin 10.9 11.2 12.1 11.3 11.1 10.5 10.5 8.8 9.2
White Cell Count (X103/ɥl) 2.6 2.6 2.2 4.9
AST (IU/l) 112 93
ALT (IU/l 95 74




*Platelet (4 units) and Red cell concentrate (1 unit) were transfused on 14/7/2011.
The ‘leakage’ or critical phase was from 12/7/2012 to 14/7/2012.
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Conclusion
Dengue is a life threatening illness affecting thousands
of patients during epidemics. Some of them may have
added complications such as being on mandatory antic-
oagulation. Guidelines on managing such patients are
nonexistent in published literature. Our experience with
this patient stresses that careful monitoring and plan-
ning of management ahead of projected changes in
platelet counts can be life saving. However, the same
protocol may not be valid for a second patient. There-
fore it is important that clinicians share their experi-
ences in managing such difficult patients.
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